Question Everything. See who's reporting it.

mRNA Vaccine Cuts Melanoma Recurrence Risk by 42% in Trial

Source: Wired

The story in brief

An experimental mRNA vaccine reduced melanoma recurrence risk by 42% when combined with Pembrolizumab, with 82.2% of patients remaining recurrence-free after 24.6 months. The therapy, personalized to each patient’s tumor, is under investigation for approval and remains in trials to confirm its efficacy.

NEWXFree on Android and iPhone. Open in NEWX